DHTs promise faster, more inclusive trials, but they must be implemented correctly. ICON’s latest whitepaper is a must-read for organizations looking to deploy digital measures in their trials. The whitepaper offers step...

For the third and final article in our series, ICON’s regulatory expert Jeremy Tinkler discusses ISO 10993-1 in the context of risk estimation. This article looks at the upcoming revision of ISO 10993-1, which has spar...

Patient recruitment strategies need to evolve to ensure the best data from a wider range of patients. Meet ICON experts at #ASH25, booth \#2161 to learn how our strategic solutions and innovative methods help reduce pati...

On December 8-10 at CVCT, speak with our cardio-metabolic drug development experts about how we’re helping to address the challenges of CV trials and improve outcomes through more efficient trial design, effective use of...

Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists. If you ar...

High-risk medical devices and IVDs enter the JCA process in 2026. Are you prepared for what’s next? ICON’s whitepaper outlines what developers need to know—now. Read more: https://ow.ly/2wWF50XgHL8 #MedTech #IVD #JCA #H...

15+ years of healthcare data. Weekly and monthly. Metys®, from Symphony Health, and ICON plc company, gives you unmatched historical depth to track product trends, market shifts, and lifecycle performance with precisio...

ICH GCP E6(R3) is here. Are you ready to lead the change? The global clinical research landscape is evolving and ICON is at the forefront. Join our upcoming Xtalks webinar to explore the impact, assess the risk and defi...

ICH GCP E6(R3): The Future Starts Now The final version of ICH GCP E6(R3) is here—and it’s changing the way we design and conduct clinical trials. ICON’s regulatory experts will guide you through what’s new, what’s crit...

In today’s data-rich healthcare landscape, open claims datasets offer unmatched breadth and timeliness. But disruptions—whether from new sources or supplier exits—are inevitable. Join Symphony Health, an ICON plc compan...

Open claims datasets are a goldmine for life sciences—but they come with inevitable disruptions. Whether it’s new data sources or supplier exits, knowing how to manage change is key to maintaining strategic advantage. J...

As we mark World Antimicrobial Awareness Week, it’s time to spotlight innovative solutions to AMR. ICON’s article examines bacteriophage therapy and its potential to fight multidrug-resistant infections. Learn more: htt...